Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...

Conversion therapy has become a hot topic among specialists in gastrointestinal cancers, said Pamela Kunz, MD, of the Yale ...

Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction ...

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

The best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear ... within 5 cm of the esophagogastric junction and extension into the esophagus were eligible.

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

in the first-line treatment of patients with locally advanced unresectable or metastatic HER 2-negative gastroesophageal adenocarcinoma. However, the companies said the study missed its other ...

“Gastric and gastroesophageal cancers continue to present challenges due to their heterogeneity and generally poor prognoses,” said Dr Corina Dutcus, Senior Vice President, Oncology Global ...

Gregory Lubiniecki, vice president of global clinical development at Merck Research Laboratories, said: “Locally advanced unresectable or metastatic gastroesophageal adenocarcinoma remains a ...